Contribution seq 13536

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "nature-levetiracetam-caveat",
      "title": "Levetiracetam therapeutically targets GABAergic synapses in diffuse midline glioma",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-28T23:17:21Z",
      "canonical_uri": "https://www.nature.com/articles/s41591-026-04646-6"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "nature-levetiracetam-caveat-quote",
      "excerpt": "Important caveats are that these data are retrospective, the numbers are small and levetiracetam should be studied in future prospective clinical studies with stratification by molecular subtype and DMG location before drawing conclusions.",
      "locator": {},
      "source_id": "nature-levetiracetam-caveat",
      "excerpt_hash": "sha256:54db36b8648cf72c0d9f5a27290720582f972dfe1cc12501f140368262193c39",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "nature-levetiracetam-caveat-evidence",
      "statement": "The authors caution that the survival association comes from small retrospective data and needs prospective studies before treatment conclusions.",
      "observation_type": "EXPERT_ANALYSIS",
      "source_location_id": "nature-levetiracetam-caveat-quote"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "The claim correctly says “linked,” but the evidence is retrospective with small numbers and does not establish a causal treatment effect.",
      "claim_id": "250d20d0-ff02-8715-9494-aa3befe833a9",
      "direction": "QUALIFY",
      "evidence_item_id": "nature-levetiracetam-caveat-evidence",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND",
  "searched": "Read the counted Stanford passage and the peer-reviewed Nature Medicine article. Checked time range, population, denominator, baseline, sampling, and study design. A material qualifier is that the patient evidence is retrospective and small, so prospective trials are needed before causal treatment conclusions."
}

Rows created

• Source 01ecc461-99d5-86e5-998b-65b8ec282d05
• SourceLocation 4daef971-f00d-8e55-9afb-c411f022badb
• EvidenceItem e9bf293e-c0f8-84a4-ad38-cf4d91ea1158
• EvidenceClaimLink fbc6f2b4-4a51-8610-a646-37ef99a2bf03 (accepted seq 13537)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"science","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}